Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence

Conditions:   Hepatocellular Carcinoma;   TACE;   Anlotinib Interventions:   Drug: Anlotinib Hydrochloride;   Procedure: TACE Sponsors:   First Affiliated Hospital Xi'an Jiaotong University;   Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials